Cargando…

Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer

Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wills, Beatriz, Brahmer, Julie R., Naidoo, Jarushka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Lung Cancer (HA Wakelee, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102206/ https://www.ncbi.nlm.nih.gov/pubmed/30101402 http://dx.doi.org/10.1007/s11864-018-0562-9

Ejemplares similares

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
por: Mhanna, Laurent, et al.
Publicado: (2019)

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer
por: Nosaki, Kaname, et al.
Publicado: (2015)

Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer
por: Chandrasekar, Divya, et al.
Publicado: (2016)

A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
por: McGranahan, Tresa, et al.
Publicado: (2017)

Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies
por: Chen, Xuguang, et al.
Publicado: (2021)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors
por: Lu, Shun, et al.
Publicado: (2019)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients
por: Møller, Henrik, et al.
Publicado: (2018)

IMPACT OF COVID-19 PANDEMIC ON DIAGNOSIS AND TREATMENT OF LUNG CANCER IN THE VETERAN COHORT
por: ABBAS, HATOON, et al.
Publicado: (2021)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
por: Schlick, Brian, et al.
Publicado: (2022)

Management of Lung Cancer in the Patient with Interstitial Lung Disease
por: Frank, Angela J, et al.
Publicado: (2022)

LDCT lung cancer screening in populations at different risk for lung cancer
por: Teles, Gustavo Borges da Silva, et al.
Publicado: (2020)

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
por: Hall, Helen, et al.
Publicado: (2022)

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach
por: Popat, Sanjay, et al.
Publicado: (2020)

Potential applications of prognostic and immunological marker transmembrane serine proteinase 2 in prediction, prevention and personalized treatment of lung cancer
por: Mu, Bo, et al.
Publicado: (2022)

Treatment Paradigms for Advanced Non‐Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
por: Aggarwal, Charu, et al.
Publicado: (2017)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Initial experience with transbronchial cryoablation as a novel local treatment for malignant peripheral lung lesions
por: Kohno, Mitsutomo, et al.
Publicado: (2018)

A Modified Calculation Improves the Accuracy of Predicted Postoperative Lung Function Values in Lung Cancer Patients
por: Schlachtenberger, G., et al.
Publicado: (2021)

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer
por: Fintelmann, Florian J., et al.
Publicado: (2019)

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
por: Zhang, Lei, et al.
Publicado: (2022)

Performance monitoring of EBUS for the staging and diagnosis of lung cancer: auditing the Greater Manchester EBUS service against new national standards
por: Punjabi, Anshu, et al.
Publicado: (2021)

UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening
por: Field, J K, et al.
Publicado: (2016)

Analysis of lung cancer risk model (PLCO(M2012) and LLP(v2)) performance in a community-based lung cancer screening programme
por: Lebrett, Mikey B, et al.
Publicado: (2020)

Prevalence and outcome of central airway obstruction in patients with lung cancer
por: Daneshvar, Cyrus, et al.
Publicado: (2019)

Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
por: Avancini, Alice, et al.
Publicado: (2019)

Evaluation of cardiovascular risk in a lung cancer screening cohort
por: Ruparel, Mamta, et al.
Publicado: (2019)

Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
por: Taylor, Sally, et al.
Publicado: (2021)

Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT)
por: Kummer, Sonja, et al.
Publicado: (2020)

Responding to symptoms suggestive of lung cancer: a qualitative interview study
por: Birt, Linda, et al.
Publicado: (2014)

Diffuse Alveolar Hemorrhage in a Patient Receiving Bevacizumab for Lung Cancer
por: Sethi, Sakshi, et al.
Publicado: (2014)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Image enhancement technology in bronchoscopy: a prospective multicentre study in lung cancer
por: van der Heijden, Erik H F M, et al.
Publicado: (2018)

Defining the information needs of lung cancer screening participants: a qualitative study
por: Ruparel, Mamta, et al.
Publicado: (2019)

Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery
por: Doerr, Fabian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rfgjuppv8ee8q91p2jqsm1215g